AgomAb Therapeutics raises USD 23.5 million for its agomAbs

A Belgian biotherapeutics company AgomAb Therapeutics which has been in a long run of making agonistic antibodies has secured USD 23.5 million in a Series A financing round from international investor syndicate co-led by V-Bio Ventures (Belgium) and Advent France Biotechnology (France), and joined by Boehringer Ingelheim Venture Fund (Germany), Omnes (France) and Pontifax (Israel). Agonistic monoclonal antibodies (agomAbs) can potentially treat a variety of fibrotic, inflammatory, autoimmune and degenerative diseases.

Allergan’s eye drug Abicipar fails

Considered one of the six stars Allergan’s EYE drug ‘Abicipar’ was considered an equivalent to Novartis’s Lucentis (ranibizumab), but the least promising results during the trials and 15% inflammatory chances reduced to 8.9%  have dwindled the faith of  Wall Street analysts. In a road ahead, Allergan plans to file a Biologics License Application by the end of June.

Good news for the patients suffering from Type-I diabetes

With Insulin prices skyrocketing and the mounting public pressure, the insurance giant Cigna and its drug benefit arm, Express Scripts, has decided to reduce the price of insulin from USD 40 to USD 25 per month, on an average. The reduction of out-of-pocket costs of the lifesaving drug would help save money and result in patients not cutting on their Insulin dosage.

Dyne Therapeutics comes to life

Dyne Therapeutics founded, seeded and incubated by the Life science VC Atlas Venture and has raised USD 50 million series A funding from Amgen, Editas Medicine, Merck, and Sarepta Therapeutics. Dyne will be solely focused on antibody conjugates to deliver nucleic acids and other molecules for the treatment of serious muscle diseases.